Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Atkins

Showing results (161-170 of 493) with videos related to

Pageof 50
Sort By:
Future Oncology (London, England)|April 20, 2022
Real-world treatment patterns and overall survival in <i>BRAF</i>-mutant melanoma patients treated with immunotherapy or targeted therapyMichael B Atkins, Cristina Julian, Matthew H Secrest, et al.
Blood|November 15, 1991
Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytesG Vachino, J A Gelfand, M B Atkins, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 1996
Lag phase quantification for solid gastric emptying studiesH A Ziessman, F B Atkins, U S Vemulakonda, et al.
The Journal of Investigative Dermatology|March 11, 2011
Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control studyClara Curiel-Lewandrowski, Tamar Nijsten, Maria L Gomez, et al.
Melanoma Research|September 9, 2010
Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanomaAmy Frankenthaler, Ryan J Sullivan, Wei Wang, et al.
Synapse (New York, N.Y.)|July 10, 1999
Region-specific induction of deltaFosB by repeated administration of typical versus atypical antipsychotic drugsJ B Atkins, J Chlan-Fourney, H E Nye, et al.
European Cytokine Network|April 22, 1999
Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapyE Vannier, A Kaser, M B Atkins, et al.
Journal of Immunological Methods|August 9, 1993
A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapyH Tilg, D Pape, E Trehu, et al.
European Radiology|December 6, 2001
Multiphase contrast-enhanced helical CT of liver metastases from renal cell carcinomaV D Raptopoulos, S P Blake, K Weisinger, et al.
International Journal of Radiation Oncology, Biology, Physics|May 1, 2016
Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)Christopher J Anker, Kenneth F Grossmann, Michael B Atkins, et al.
Pageof 50

Showing results (161-170 of 493) with videos related to

Sort By:
Pageof 50
Future Oncology (London, England)|April 20, 2022
Real-world treatment patterns and overall survival in <i>BRAF</i>-mutant melanoma patients treated with immunotherapy or targeted therapyMichael B Atkins, Cristina Julian, Matthew H Secrest, et al.
Blood|November 15, 1991
Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytesG Vachino, J A Gelfand, M B Atkins, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 1996
Lag phase quantification for solid gastric emptying studiesH A Ziessman, F B Atkins, U S Vemulakonda, et al.
The Journal of Investigative Dermatology|March 11, 2011
Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control studyClara Curiel-Lewandrowski, Tamar Nijsten, Maria L Gomez, et al.
Melanoma Research|September 9, 2010
Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanomaAmy Frankenthaler, Ryan J Sullivan, Wei Wang, et al.
Synapse (New York, N.Y.)|July 10, 1999
Region-specific induction of deltaFosB by repeated administration of typical versus atypical antipsychotic drugsJ B Atkins, J Chlan-Fourney, H E Nye, et al.
European Cytokine Network|April 22, 1999
Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapyE Vannier, A Kaser, M B Atkins, et al.
Journal of Immunological Methods|August 9, 1993
A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapyH Tilg, D Pape, E Trehu, et al.
European Radiology|December 6, 2001
Multiphase contrast-enhanced helical CT of liver metastases from renal cell carcinomaV D Raptopoulos, S P Blake, K Weisinger, et al.
International Journal of Radiation Oncology, Biology, Physics|May 1, 2016
Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)Christopher J Anker, Kenneth F Grossmann, Michael B Atkins, et al.
Pageof 50